RiXOVA-new approach of cancer treatment G-blocks generation II

Scientists at NTNU have recently discovered that RiXOVA, a novel drug candidate based on a matrix modifying technology platform known as G-blocks, exhibits anti-cancer properties and enhances effect of chemotherapeutics. RiXOVA has demonstrated efficacy in a mouse in vivo pancreatic and ovarian cancer models both as an enhancer of standard of care (SOC) treatment, and as a single agent. RiXOVA may thus represent a platform technology applicable to any solid tumour. RiXOVA has an excellent safety profile and its unique molecular component and proposed mode of action would represent a first in class therapeutic to the market. However, there is a need to demonstrate the efficacy of RiXOVA in several tumour models besides pancreatic and ovarian cancer, and to provide data supporting the mode of action. The aim of this project is to demonstrate the anti-cancer effect of RiXOVA in breast cancer models and to provide data confirming the mode of action of RiXOVA. Previously (described in FOTS 7875) we performed experiments verifying anti-cancer effects using the first generation of the RiXOVA-drug in various breast cancer cell lines. The scientific team has now made small adjustments/improvements of the compound leading to G-blocks generation II. The purpose of this project (FOTS 10362) is to demonstrate the anti-cancer effect of G-blocks generation II in breast tumors in mice.